Fw: MS research study with Dr. Murray/ Dr. Melamed

[Guest guest]

MS research study with Dr. Murray/ Dr. Melamed

http://e2ma.net/map/view=CampaignPublic/id=31451.10551921762/rid=40434b0dfef8289\

1fb0b71f092533146

___________________________________

CLINICAL TRIAL

A number of therapies currently available for Multiple Sclerosis are able to

prevent damage from MS. However, none are able to repair damaged nerve tissue.

This is a critical issue, especially for people with MS who already have some

level of MS-related disability.

A new experimental drug is being tested that MAY address this critical gap in MS

care. But before that can happen, this drug must be shown to be safe to

administer to people with MS.

Dr. Murray and Dr. Isaac Melamed are seeking participants with MS who are

willing to participate in a phase I trial to be among the first to receive this

experimental drug.

Qualifications Include:

Be between the age of 18-60

Have a body mass index 30 (cannot be obese, okay if merely overweight)

Have relapsing remitting OR secondary progressive MS (not primary progressive

MS)

Must be able to walk independently or with a cane for about 100 meters (may not

participate if you depend on a walker)

Treatment with interferon beta (INF) or glatiramer acetate (GA) is allowed to

continue during the study if therapy is stable for three months. Patients on

Tysabri, Rituximab, Novantrone, or Fingolimod are not eligible to participate.

The study will last for 24 weeks. Compensation for time and travel will be

provided.

If you believe you meet some of the criteria and are interested in participating

in this important clinical trial, please call IMMUNOe International Research

Centers at for more information.

Rocky Mountain Multiple Sclerosis Center

8845 Wagner St. | Westminster, CO 80031

___________________________________

forward this email to a friend

http://e2ma.net/app/view:Forward/ID:31451.10551921762/send_to_friend/rid:40434b0\

dfef82891fb0b71f092533146

This email was sent to dudleydelany@....

To ensure that you continue receiving our emails,

please add us to your address book or safe list.

manage your preferences

(http://e2ma.net/app/view:Manage/signupId:53280/id:31451.10551921762/rid:40434b0\

dfef82891fb0b71f092533146)

opt out

(http://e2ma.net/app/view:OptOut/signupId:53280/ID:31451.10551921762/rid:40434b0\

dfef82891fb0b71f092533146) using TrueRemove®.

Got this as a forward? Sign up

(http://e2ma.net/app/view:Join/signupId:53280/acctId:31451/mailingId:3784793/rid\

:40434b0dfef82891fb0b71f092533146) to receive our future emails.

email powered by Emma®

http://www.myemma.com/